Story

AMD, Moderna Shares Surge on Positive Analyst Upgrades

ENTHMSVIIDZHZH-TWJAKOHI
Aug 25, 20261 min read
AMD, Moderna Shares Surge on Positive Analyst Upgrades
Text size
Background

Shares of Advanced Micro Devices (AMD) and Moderna (MRNA) surged on Tuesday, driven by positive analyst upgrades that underscored investor optimism in the artificial intelligence and biotechnology sectors. Technology hardware firm Dell (DELL) also posted significant gains, joining a wide range of stocks moving higher during the session.

Analyst Actions Drive Key Movers

Advanced Micro Devices stock climbed 4.67% after Raymond James upgraded its rating on the chipmaker. According to market data reported by Investing.com, the investment firm cited a strong outlook for AI server growth as the primary catalyst for its positive revision.

In the biotechnology space, Moderna experienced a substantial rally, with its shares jumping 13.54%. The move followed an upgrade from Wolfe Research, which reportedly revised its stance on the company based on favorable clinical trial results.

Broader Tech and Growth Gains

The positive sentiment extended to other major technology firms and growth-oriented stocks. Dell Inc. was a notable mega-cap mover, with its stock rising 3.48%. Super Micro Computer (SMCI), another company closely linked to the AI hardware boom, gained 8.91%.

Sample IUX Markets – In-articleAd

Other significant performers across various market capitalizations on Tuesday included:

  • Robinhood Markets (HOOD): +7.32%
  • Futu Holdings (FUTU): +8.87%
  • Rumble (RUM): +11.27%
  • Generate Biomedicines (GENB): +11.57%
  • Richtech Robotics (RR): +18.52%

Market Context

Tuesday's trading activity highlights the market's continued sensitivity to company-specific news, particularly analyst ratings tied to major secular growth themes like artificial intelligence. The gains in AMD and Super Micro Computer reflect persistent investor appetite for companies positioned to benefit from the ongoing AI infrastructure buildout.

Similarly, Moderna's sharp increase demonstrates the high-impact nature of clinical data and subsequent analyst re-evaluations within the often-volatile biotech industry. These targeted rallies suggest investors are actively seeking catalysts in specific sectors rather than relying solely on broad market momentum.

Read next

More on Stocks
Back to latest news

LATEST